MetaVia Reports Positive Phase 1b Clinical Trial Results for Obesity Drug DA-1726
MTVA sits 54% above its 52-week low of $6.05 on light trading volume (0.1× avg).
Summary
MetaVia Inc. announced positive, statistically significant Phase 1b clinical trial results for its obesity drug DA-1726, showing robust weight loss, improved glucose control, and a favorable safety profile.
Key Events · Product Development and Regulatory · MTVA
-
Positive Phase 1b Trial Results
MetaVia announced statistically significant positive results from the 8-week, non-titrated 48 mg cohort of its Phase 1b clinical trial for DA-1726, a novel dual GLP1R/GCGR agonist for the treatment of obesity.
-
Robust Weight Loss and Metabolic Improvements
Patients achieved an average 9.1% weight reduction (21.2 lbs) and a statistically significant 9.8 cm reduction in waist circumference by Day 54. Fasted glucose improved by 12.3 mg/dL, and liver stiffness (VCTE) reduced by 23.7%.
-
Favorable Safety Profile
The trial reported no treatment-related discontinuations, with gastrointestinal events being mild to moderate in severity, indicating good tolerability for DA-1726.
-
Differentiated Potential Highlighted
CEO Hyung Heon Kim emphasized the drug's potential as a 'best-in-class treatment option' due to its compelling balance of weight loss, metabolic improvement, direct hepatic benefit, and tolerability.
Analysis · MTVA · Life Sciences
MetaVia Inc., a clinical-stage biotechnology company, announced highly encouraging Phase 1b clinical trial results for its obesity drug candidate, DA-1726. The data demonstrated statistically significant weight loss, improved glucose control, and notable reductions in liver stiffness, alongside a favorable safety profile. These positive outcomes for a dual GLP1R/GCGR agonist in a competitive market are a significant de-risking event for the company and could substantially enhance its valuation and future development prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $9.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22M. The 52-week trading range was $6.05 to $30.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.